Queymi N° 23

Revista de difusión cultural, publicada por el INC, filial Ancash, en setiembre de 1983. Cuenta con la colaboración de autores locales y notas informativas sobre la actividad institucional del INC-FA. Contiene: Nota Editorial – Cartas -- Homenaje al libertador Simón Bolívar en el Bicentenario de su nacimiento – Discurso de orden, 21 de julio. Carás, por Francisco Gonzáles -- Discurso de orden, 24 de julio. Plazuela Bolívar de Huarás, por Francisco Gonzáles – Itinerario y cronología de Bolívar en el norte del Perú, por Manuel S. Reyna L. – Bolívar y la amistad, por Sergio Quijada Jara – La última frase de Bolívar – tradición de Ricardo Palma – Actividades del INC-DA – Ancash en la historia. El ambiente revolucionario en Ancash a la llegada de Luzuriaga, por Augusto Alba Herrera – Personajes. Ladislao F. Meza, por Pedro Barrantes – Aurelio Arnao Loli, por Juan de Dios Alba

Queymi N° 20

Revista de difusión cultural, publicada por el INC, filial Ancash, en diciembre de 1982. Cuenta con la colaboración de autores locales y notas informativas sobre la actividad institucional del INC-FA. Contiene: Nota editorial -- Cartas -- Ancash en la Historia. El periodismo huaracino en la década de los 30, por Manuel S. Reina Loli -- La diócesis de Huarás, por Eduardo Velásquez T. -- Primeras manifestaciones culturales en el Departamento de Ancash, por Juan de Dios Alba -- Personajes. Pedro C. Kochatzin de la Cruz “Uchcu Pedro”, por Santiago Maguiña -- Actividades del INC-FA -- Astronomía andina, por Rubén Almendrades Z. -- Crónicas. Ecos de una Actuación Musical Inolvidable, por Francisco Gonzáles – El entierro de la Manta y el Pañolón, por Francisco Gonzáles -- Transcripción. Una excursión trasandina (del Boletín de la Soc. Geog. Lima T.XV año XIV) -- Poética. El viajante, por Herbert Sawanay

Queymi N° 27

Revista de difusión cultural, publicada por el INC, filial Ancash, en setiembre de 1984. Cuenta con la colaboración de autores locales y notas informativas sobre la actividad institucional del INC-FA. Contiene: Nota Editorial – Cartas -- Ancash en la Historia. La erección de la diócesis de Huaraz, por Manuel S. Reyna Loli – Arqueología. Chavín (de Huántar) en proceso de ser declarado patrimonio monumental, por Martin Flores -- Transcripción. Colección de autores ancashinos, por Cristóbal Bustos Ch. – Opinión. Identidad Regional, por Rubén Almendradez Z. – Discursos. “Doña Nati” y “Estampas de mi madre” – Turismo. Guía de turismo “Ancash”, por Teófilo Maguiña Cueva – Fiesta patronal Santa Isabel de Huaylas, por Juan de Dios Alba – Evocación. Noche de San Juan, por María Turriate de Roca – Folklore. “Illa Rumi”, por Santiago Maguiña Chauca – Literaria. El lorito que se fue, por Francisco Gonzales – Actividades del INC-DA

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Architecture and performance of the KM3NeT front-end firmware

The KM3NeT infrastructure consists of two deep-sea neutrino telescopes being deployed in the Mediterranean Sea. The telescopes will detect extraterrestrial and atmospheric neutrinos by means of the incident photons induced by the passage of relativistic charged particles through the seawater as a consequence of a neutrino interaction. The telescopes are configured in a three-dimensional grid of digital optical modules, each hosting 31 photomultipliers. The photomultiplier signals produced by the incident Cherenkov photons are converted into digital information consisting of the integrated pulse duration and the time at which it surpasses a chosen threshold. The digitization is done by means of time to digital converters (TDCs) embedded in the field programmable gate array of the central logic board. Subsequently, a state machine formats the acquired data for its transmission to shore. We present the architecture and performance of the front-end firmware consisting of the TDCs and the state machine